Grants and Contributions:
Title:
COVID-19 Response: Development of novel COVID-19 Therapeutics utilizing Precision Medicine approach
Agreement Number:
960289
Agreement Value:
$4,609,000.00
Agreement Date:
Oct 5, 2020 - Mar 31, 2023
Description:
Development of a proprietary biological drug to block Coronavirus infectivity, whilst reducing induced pathology in symptomatic patients, permitting a faster recovery and avoiding multiple organ injuries
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H3B 4W5
Reference Number:
172-2020-2021-Q3-960289
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
726018930
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 59 days.
Amendment Date
Jan 3, 2023
Recipient's Legal Name:
JN NOVA PHARMA INC
Federal Riding Name:
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number:
24077
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254
Amendments: